• News
    • Latest news
    • News search
    • Health
    • Finance
    • Food
    • Career news
    • Content series
    • Try Devex Pro
  • Jobs
    • Job search
    • Post a job
    • Employer search
    • CV Writing
    • Upcoming career events
    • Try Career Account
  • Funding
    • Funding search
    • Funding news
  • Talent
    • Candidate search
    • Devex Talent Solutions
  • Events
    • Upcoming and past events
    • Partner on an event
  • Post a job
  • About
      • About us
      • Membership
      • Newsletters
      • Advertising partnerships
      • Devex Talent Solutions
      • Contact us
Join DevexSign in
Join DevexSign in

News

  • Latest news
  • News search
  • Health
  • Finance
  • Food
  • Career news
  • Content series
  • Try Devex Pro

Jobs

  • Job search
  • Post a job
  • Employer search
  • CV Writing
  • Upcoming career events
  • Try Career Account

Funding

  • Funding search
  • Funding news

Talent

  • Candidate search
  • Devex Talent Solutions

Events

  • Upcoming and past events
  • Partner on an event
Post a job

About

  • About us
  • Membership
  • Newsletters
  • Advertising partnerships
  • Devex Talent Solutions
  • Contact us
  • My Devex
  • Update my profile % complete
  • Account & privacy settings
  • My saved jobs
  • Manage newsletters
  • Support
  • Sign out
Latest newsNews searchHealthFinanceFoodCareer newsContent seriesTry Devex Pro
    • News
    • HIV/AIDS

    Cabotegravir also works for women, HIV prevention study reveals

    A new study has proven that an investigational injectable drug is effective in preventing HIV among women, providing new options for women and girls.

    By Jenny Lei Ravelo // 09 November 2020
    A dispensary for anti-retroviral drugs in Nairobi, Kenya. Photo by: Thomas Mukoya / Reuters

    MANILA — An investigational injectable drug is found to be effective in preventing HIV among women, according to an interim analysis of a study published Monday,  providing new options on HIV prevention for women and girls, who account for 48% of all new HIV infections in 2019.

    Study HPTN 084, led by the HIV Prevention Trials Network, found cabotegravir, a long-acting injectable developed by ViiV Healthcare, was 89% more effective than the standard oral preexposure prophylaxis tenofovir/emtricitabine combination pills widely used for HIV prevention.

    The high effectiveness of the drug led an independent data safety monitoring board to recommend an early stop to the study, which is being conducted in 20 sites across seven countries in sub-Saharan Africa, involving over 3,200 women participants.

    Can this new injectable deliver on its promise to reduce HIV transmission?

    Clinical evidence shows that cabotegravir, an investigative injectable drug for HIV prevention and treatment, is 66% more effective than daily oral PrEP. Experts explain what barriers stand in the way of the drug's rollout.

    A separate study on cabotegravir’s effectiveness in preventing HIV among men and transgender women also ended early in May for the same reasons. In that companion study HPTN 083, cabotegravir was 66% more effective — the effectiveness range was 38% to 82% — than the oral PrEP.

    Young women are especially vulnerable to HIV infections. Every week, an estimated 5,500 young women aged 15 to 24 years old get infected with HIV. In sub-Saharan Africa, young women in this age range are twice as likely to be living with HIV than men. Girls also account for 5 in 6 new infections among adolescents aged 15 to 19 years old in the region, according to latest data from UNAIDS.

    Matteo Cassolato, technical lead for HIV prevention at Frontline AIDS, told Devex over email that results of the study mean there is not only a new method of prevention, but “potentially a better method for women and other groups who may struggle with adhering to daily pill treatment long-term.”

    “If approved, long-acting cabotegravir will provide an option that reduces the number of dosing days from 365 to six,” said Dr. Kimberly Smith, head of research & development at ViiV Healthcare. The injectable is administered every two months, as opposed to daily oral pills.

    Cassolato argued however that to reduce new HIV infections among women and girls, comprehensive multisectoral approaches that go beyond the health sector are needed — those that address issues of gender inequality and other harmful gender norms that severely limit women and girls’ ability to use HIV prevention options like PrEP.

    “These results are exciting, but it’s important to acknowledge they are a starting point.”

    — Matteo Cassolato, technical lead for HIV prevention, Frontline AIDS

    Viiv Healthcare will engage with global regulators in the coming months to prepare for regulatory submissions using results from both HPTN 083 and HPTN 084 studies on cabotegravir as a PrEP.

    Cabotegravir, as a single drug, has not received any regulatory approval to date either for HIV treatment or HIV prevention. The only known regulatory approval of cabotegravir was in Canada, where oral tablets of the drug and its injectable form — which is combined with Johnson & Johnson’s rilpivirine — received its first regulatory approval early in 2020 for HIV treatment.

    But apart from regulatory approval, countries will have to deal with delivery, access, and uptake of the drug — challenges that experts anticipate.

    “These results are exciting, but it’s important to acknowledge they are a starting point. There are now important real world implementation issues to address, from assessing how acceptable the new drug and its delivery method are, to understanding how HIV prevention programmes would need to be adjusted so that this method can be delivered safely and effectively to women and girls,” Cassolato said.

    Another potential issue is how to avoid drug resistance for those who decide to discontinue using the injectable drug.

    “It will still take some time for injectable cabotegravir to become available, but it is hopeful.” Cassolato added.

    Asked regarding affordability of cabotegravir for HIV prevention, Smith said in an email that ViiV Healthcare, “does not expect to profit from sales of its marketed products to public HIV programmes and international donor agency programmes” in low-income countries and least-developed countries, including in sub-Saharan Africa.

    “On this basis, long-acting injectable cabotegravir for HIV prevention will be offered at a non-profit price in these countries to enable countries with the greatest barriers to affordability to be sustainably supplied at the lowest possible prices,” she told Devex.

    Detailed results of the HPTN 084 study will be presented at a scientific meeting in 2021.

    • Global Health
    • Research
    • ViiV Healthcare
    • Frontline AIDS
    Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).

    About the author

    • Jenny Lei Ravelo

      Jenny Lei Ravelo@JennyLeiRavelo

      Jenny Lei Ravelo is a Devex Senior Reporter based in Manila. She covers global health, with a particular focus on the World Health Organization, and other development and humanitarian aid trends in Asia Pacific. Prior to Devex, she wrote for ABS-CBN, one of the largest broadcasting networks in the Philippines, and was a copy editor for various international scientific journals. She received her journalism degree from the University of Santo Tomas.

    Search for articles

    Related Jobs

    • Monitoring, Evaluation, Research, and Learning (MERL) Analyst
      Jakarta, Indonesia | Indonesia | East Asia and Pacific
    • Research Analyst Intern
      Global Green Growth Institute (GGGI)
      Abu Dhabi, United Arab Emirates | United Arab Emirates | North Africa and Middle East
    • RIMBA Project Coordinator (Jambi Based)
      Jambi City, Indonesia | Indonesia | East Asia and Pacific
    • See more

    Most Read

    • 1
      Opinion: Mobile credit, savings, and insurance can drive financial health
    • 2
      FCDO's top development contractors in 2024/25
    • 3
      Strengthening health systems by measuring what really matters
    • 4
      Opinion: India’s bold leadership in turning the tide for TB
    • 5
      Reigniting momentum for maternal, newborn, and child health

    Trending

    Financing for Development Conference

    The Trump Effect

    Newsletters

    Related Stories

    Global healthIs a new HIV prevention plan ambitious enough? And can it survive Trump?

    Is a new HIV prevention plan ambitious enough? And can it survive Trump?

    Global HealthFDA approves new HIV prevention tool, though access questions linger

    FDA approves new HIV prevention tool, though access questions linger

    Global HealthWill infants finally have access to a highly effective HIV drug?

    Will infants finally have access to a highly effective HIV drug?

    Global healthUSAID funding cuts jeopardize breakthrough drugs and research

    USAID funding cuts jeopardize breakthrough drugs and research

    • News
    • Jobs
    • Funding
    • Talent
    • Events

    Devex is the media platform for the global development community.

    A social enterprise, we connect and inform over 1.3 million development, health, humanitarian, and sustainability professionals through news, business intelligence, and funding & career opportunities so you can do more good for more people. We invite you to join us.

    • About us
    • Membership
    • Newsletters
    • Advertising partnerships
    • Devex Talent Solutions
    • Post a job
    • Careers at Devex
    • Contact us
    © Copyright 2000 - 2025 Devex|User Agreement|Privacy Statement